Stroke has become the first major culprit in the death of Chinese people, stroke listed drugs overview and current situation analysis.

Release time:


Recently, a woman on the train for a long time with her head tilted to play mobile games caused a stroke, the news has aroused widespread concern about stroke in the industry. Moreover, an analysis report entitled "mortality of 240 diseases in China from 1990 to 2013: a provincial level systematic analysis of the global burden of disease study in 2013" published in the international authoritative journal lancet shows that stroke causes more deaths than cancer, which is the first major culprit of killing Chinese people! Let's take a look at the disease and related drugs.

Overview of Listed Stroke Drugs

Table 1 Overview of listed stroke drugs

Stroke is what we often call stroke. It is a disease of brain tissue damage caused by cerebral vascular rupture or vascular obstruction leading to cerebral ischemia. It can be divided into ischemic stroke and hemorrhagic stroke. Among them, ischemic stroke accounts for the majority, accounting for more than 60% of the total number of strokes. In my country, there are more than 200 new cases of stroke each year, and the death toll is as high as more than 150 million per year, accounting for 22.45 percent of all deaths from various diseases, and it is also showing an upward trend year by year.

For the treatment of stroke, it is not difficult to see from the current situation that there are more than 200 million new cases and more than 150 million deaths per year. The current development status of stroke treatment drugs is not optimistic. As shown in Table 1, there are currently 6 types of stroke in the indications of global marketed drugs. including alteplase (Alteplase), aspirin/dipyridamole (Aggrenox®), heparin sodium (Heparin sodium), butylphthalide (enbipu®, Butylphthalide), rivaroxaban (Rivaroxaban), and edoxaban p-toluenesulfonate (Edoxaban Tosilate Hydrate).

Alteplase (Alteplase) is a thrombolytic drug owned by Roche, the main ingredient is glycoprotein, containing 526 amino acids. The drug can convert plasminogen into plasmin by binding to fibrin and selectively activating the plasminogen bound to fibrin. Because of its high selectivity for the activation of plasminogen, it does not cause side effects such as bleeding. It is worth mentioning that alteplase (Alteplase) is the only thrombolytic drug approved by FDA for ischemic stroke so far. Since its approval in 1996, alteplase has maintained a good market share and once entered the ranks of Roche's top ten best-selling drugs.

Edoxaban p-toluenesulfonate (Edoxaban Tosilate Hydrate) is currently the latest approved drug and is a new oral anticoagulant selective factor Xa inhibitor. The drug belongs to Japan's first three Communist Party, initially listed in Japan in 2011, and in 2015 through the United States FDA listing approval.

It is worth mentioning that among the 6 drugs shown in Table 1, butylphthalide (Enbipu®, Butylphthalide) belongs to China's Shiyao Group, is the first national class I new drug with independent intellectual property rights in the field of cerebrovascular disease treatment in China. In 2003, Shiyao Group established Enbipu Pharmaceutical Co., Ltd. In addition, butylphthalide (Enbipu®Butylphthalide) is China's first independent innovative drug with annual sales exceeding the 1 billion yuan mark, and it is a drug worthy of pride in the history of drug development in China!

Generally speaking, although some breakthroughs have been made in the development of stroke drugs at home and abroad, the treatment of stroke is far from reaching the expectation. It is hoped that in the future, through the continuous efforts of drug developers, more drugs with excellent curative effect can be developed, which will give the majority of stroke patients a perfect answer.